Print this page
-
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma STRIKE
Protocol: 082502Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Single-Arm, Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants with BCG-unresponsive High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Protocol: 082504Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Exploration of Novel AI-Enabled Blue Light Enhanced Cystoscopy.
Protocol: 082506Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Phase 3 Randomized, Open-Label Study of Pasritamig (JNJ-78278343), a T-cell-Redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082507Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer.
Protocol: 082509Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
With Advanced Clear Cell Renal Cell Carcinoma
Protocol: 082510Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered with Enfortumab Vedotin and Pembrolizumab in Participants with Advanced Urothelial Cancer
Protocol: 082602Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Other Urinary -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer.
Protocol: 082603Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Urinary Bladder -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients with Suspected Regional Disease.
Protocol: 082410Principal Investigator:
- Thomas Jang
Applicable Disease Sites: Other Urinary